HKSE - Delayed Quote HKD

INNOVENT BIO (1801.HK)

Compare
33.050
+0.050
+(0.15%)
At close: January 28 at 12:08:04 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,206,070.000
6,206,070.000
4,556,380.000
4,269,729.000
3,843,819.000
Cost of Revenue
1,136,266.000
1,136,266.000
930,990.000
505,337.000
387,761.000
Gross Profit
5,069,804.000
5,069,804.000
3,625,390.000
3,764,392.000
3,456,058.000
Operating Expense
5,979,014.000
5,979,014.000
6,207,275.000
5,703,539.000
3,498,501.000
Operating Income
-909,210.000
-909,210.000
-2,581,885.000
-1,939,147.000
-42,443.000
Net Non Operating Interest Income Expense
354,213.000
354,213.000
87,839.000
89,291.000
47,752.000
Pretax Income
-1,144,411.000
-1,144,411.000
-2,170,469.000
-2,641,717.000
-858,713.000
Tax Provision
-116,498.000
-116,498.000
8,801.000
87,038.000
139,708.000
Net Income Common Stockholders
-1,027,913.000
-1,027,913.000
-2,179,270.000
-2,728,755.000
-998,421.000
Diluted NI Available to Com Stockholders
-1,027,913.000
-1,027,913.000
-2,179,270.000
-2,728,755.000
-998,421.000
Basic EPS
-0.66
-0.66
-1.46
-1.88
-0.74
Diluted EPS
-0.66
-0.66
-1.46
-1.88
-0.74
Basic Average Shares
1,559,637.004
1,559,637.004
1,490,123.192
1,455,605.751
1,357,011.757
Diluted Average Shares
1,559,637.004
1,559,637.004
1,490,123.192
1,455,605.751
1,357,011.757
Total Expenses
7,115,280.000
7,115,280.000
7,138,265.000
6,208,876.000
3,886,262.000
Net Income from Continuing & Discontinued Operation
-1,027,913.000
-1,027,913.000
-2,179,270.000
-2,728,755.000
-998,421.000
Normalized Income
-1,054,728.840
-1,054,728.840
-2,183,141.500
-2,821,986.000
-1,020,753.000
Interest Income
452,837.000
452,837.000
189,537.000
151,755.000
116,102.000
Interest Expense
98,624.000
98,624.000
101,698.000
62,464.000
68,350.000
Net Interest Income
354,213.000
354,213.000
87,839.000
89,291.000
47,752.000
EBIT
-1,045,787.000
-1,045,787.000
-2,068,771.000
-2,579,253.000
-790,363.000
EBITDA
-660,684.000
-660,684.000
-1,749,349.000
-2,374,506.000
-704,736.000
Reconciled Cost of Revenue
1,136,266.000
1,136,266.000
930,990.000
505,337.000
387,761.000
Reconciled Depreciation
385,103.000
385,103.000
319,422.000
204,747.000
85,627.000
Net Income from Continuing Operation Net Minority Interest
-1,027,913.000
-1,027,913.000
-2,179,270.000
-2,728,755.000
-998,421.000
Total Unusual Items Excluding Goodwill
29,855.000
29,855.000
5,162.000
124,308.000
29,776.000
Total Unusual Items
29,855.000
29,855.000
5,162.000
124,308.000
29,776.000
Normalized EBITDA
-690,539.000
-690,539.000
-1,754,511.000
-2,498,814.000
-734,512.000
Tax Rate for Calcs
0.000
0.000
0.000
0.000
0.000
Tax Effect of Unusual Items
3,039.160
3,039.160
1,290.500
31,077.000
7,444.000
12/31/2020 - 10/31/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1877.HK JUNSHI BIO
11.000
-2.83%
 
6160.HK BeiGene, Ltd.
138.200
+3.21%
 
6855.HK Ascentage Pharma Group International
33.950
-3.00%
 
RADX Radiopharm Theranostics Limited
4.7500
-0.21%
 
3759.HK Pharmaron Beijing Co., Ltd.
14.100
-1.40%
 
2142.HK HBM Holdings Limited
3.660
+3.68%
 
1672.HK ASCLETIS-B
4.050
-0.74%
 
1548.HK GENSCRIPT BIO
10.680
+1.33%
 
9688.HK Zai Lab Limited
20.900
+1.95%
 
2269.HK WuXi Biologics (Cayman) Inc.
18.420
-0.22%